DVA vs VNDA: fair value comparison
DaVita Inc. and Vanda Pharmaceuticals Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, VNDA currently sits closer to the top of our discount ranking. DVA carries the stronger quality grade.
| DVA | VNDA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $180.68 | $5.23 |
| 12-month range | $111.19–$240.09 | $4.47–$8.25 |
| Sector rank | #39 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | C | D |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: DVA fair value analysis · VNDA fair value analysis